Labcorp Analysts Stay Bullish as Options Turn Cautious Before Q3 Print

Labcorp Holdings reports Q3 results on October 28, carrying a 5.6% one-month price gain into the print and a Street that has been steadily raising targets all year.

Options positioning has grown more defensive as the date approaches. The put/call ratio reached 1.20 on October 23, above its 20-day average of 1.17 and running at roughly 1.4 standard deviations above the recent mean. That is not an extreme reading, the 52-week range runs from 0.27 to 3.30, but the drift higher over the past month is consistent with investors adding more downside protection as the print approaches. The stock closed at $328.95, up 3.5% on the week, broadly in line with the diagnostics peer group. Closest comparable Quest Diagnostics gained 2.9% over the same period, keeping the subsector tone broadly constructive.

Analyst sentiment has been one of the more consistent stories on Labcorp in 2026. Multiple firms lifted targets after the Q2 print in late July, including JP Morgan to $360 and Morgan Stanley to $338, both maintaining positive ratings. After the September interim event, Truist raised its target to $365 and UBS moved to $380, both reiterating Buy. The mean target across the consensus sits at $345, a modest premium to the current price. Barclays, holding an Equal-Weight rating, is the clearest dissenter in the recent activity, raising its target only to $330 and sitting closest to where the stock is trading. The bull case centres on the Central Lab segment's 7.5% revenue growth driven by trial wins and new AI-assisted digital pathology tools, alongside Diagnostic segment growth of 8.9% year-over-year and a $8.71 billion backlog with a net book-to-bill of 1.11x. Bears point to reimbursement headwinds under PAMA, acquisition integration risk, and organic volume growth that has been running slightly below Street expectations.

Short interest does not add much to the bearish case. At 3.0% of the free float, it has actually declined about 5% over the past week, with borrowing costs running below 1% and borrow availability at roughly 50x the current short interest. That points to a lending market with no tension whatsoever. The ORTEX short score of 35, which has drifted lower from 36 over the past two weeks, places Labcorp in a below-median position on bearish positioning relative to the broader universe.

The more interesting ownership note is on the institutional side, where Boston Partners added roughly 683,000 shares in the period through August and FMR added around 621,000, both materially larger moves than the incremental adjustments seen elsewhere in the register. Insider activity over the past 90 days has been modestly net negative in aggregate, roughly $3.5 million in net sales, though the CEO and a director both traded under pre-arranged 10b5-1 plans, which limits the informational weight of those transactions.

The October 28 print is less a test of whether Labcorp is growing and more a question of whether volume in Diagnostics is recovering toward consensus assumptions and whether the Central Lab backlog is converting at the margin profile the Street's targets now assume.